Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-IE1
- Development stage
- Unknown
- Lead developer
- City of Hope
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-IE1 is an investigational viral vector vaccine developed to prevent or manage Cytomegalovirus (CMV) complications, particularly in immunocompromised populations such as hematopoietic stem cell transplant (HCT) recipients. The vaccine utilizes the Modified Vaccinia Ankara (MVA) platform—a highly attenuated, non-replicating orthopoxvirus—to deliver and express the CMV Immediate-Early 1 (IE1) protein. IE1 is a critical regulatory protein expressed early during CMV infection and serves as a primary target for the host's cellular immune response. By presenting this antigen, MVA-IE1 aims to stimulate and expand CMV-specific CD4+ and CD8+ T-cell populations, enhancing the patient's ability to control viral replication and reducing the risk of CMV-related disease. It has been evaluated in clinical trials both as a standalone agent and in combination with other MVA-based CMV antigens.
- Other names
- Modified Vaccinia Ankara-Immediate Early 1MVA-CMV-IE1MVA-CMV-IE-1MVA-CMV-IE 1
02
Targets
IE1 (HCMV immediate-early protein 1)
Beyond the preview
Go deeper on MVA-IE1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-IE1.